Verastem Inc.

01/14/2025 | Press release | Distributed by Public on 01/14/2025 06:48

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.